Herein, we chose to focus on STAT3 because it is a key oncogenic TF involved in antitumor immune response mechanisms, and research on STAT3 and NSCLC has revealed that this TF participates in mechanisms of drug resistance to immune checkpoint inhibitors. This evidence concerns the gene TF and non-small cell lung carcinoma.